Cooperative Agreement U01CA293474
Award Date
9/6/24
Completion Date
8/31/29
Dollars Obligated
$625K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Cooperative Agreement
Place of Performance
Tampa, FL 33602, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory provides $640,583 to enhance the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor activity within the tumor microenvironment. The research aims to delineate the mechanisms by which PPARD activation improves CD8+ T cell...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $639,882 to the University of North Carolina at Chapel Hill to conduct research aimed at elucidating the molecular mechanisms underlying metastasis organ tropism in breast cancer. The project will utilize a comprehensive dataset of human primary and metastatic tumor samples, as well as genetically engineered mouse models, to identify the molecular determinants driving lung and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to Beth Israel Deaconess Medical Center, Inc. (BIDMC) provides $749,474 to conduct research aimed at understanding the underlying mechanisms of failed inflammation resolution in chemical-induced cancers. The research will focus on profiling lipid autacoid mediators, including eicosanoids and specialized pro-resolving mediators (SPMs), as well as cytokines, to evaluate their role in regulating...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Florida aims to characterize a bacterial-derived metabolite called BAC429 and its role in enhancing the efficacy of anti-PD-1 immunotherapy for non-small cell lung cancer (NSCLC). The $540,288 award, active from May 1, 2025 to April 30, 2030, will support research with the following key objectives: 1) Define the functional impact of BAC429 on experimental NSCLC, 2) Establish...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program "Cancer Biology Research" (CFDA 93.396), supports research to profile patient-specific tumor-microbiome interactions and conduct quantitative molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The $400,890 award to the Cleveland Clinic Lerner College of Medicine of Case...
This $181,640 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by a clinical scientist at The University of Texas MD Anderson Cancer Center. The primary objectives are to: Expand on the role of liquid biopsy biomarkers, specifically circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA), to generate novel combination immunotherapy trials for colorectal and anal cancers. This includes analyzing samples from...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $600,499.00 to The Trustees of Columbia University in the City of New York to conduct research on the role of the bacterium Fusobacterium nucleatum (FN) and the protein Annexin A1 (ANXA1) in the development and progression of colorectal cancer. The 5-year project, beginning on April 1, 2025, aims to investigate the mechanisms by which amyloid-like changes...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $333,504 to The Washington University to conduct research on the role of peritoneal myeloid cells in colorectal cancer peritoneal metastasis and implications for immunotherapy. The award commences on July 1, 2025 and is scheduled for completion by July 31, 2027. The key objectives of this research project are to: Profile immune cell phenotypical changes in the peritoneal fluid and...